|
About
Clinical
Trials
at
Somerset
Skin
Centre
Dr.
Murakawa
has
extensive
experience
in
conducting
clinical
trials
research.
His
initial
research
studies
were at
Albany
Medical
College.
Since
his
arrival
in late
2000,
Dr.
Murakawa
developed
the
Clinical
Trials
Group
for
University
Dermatology
and
Wayne
State.
Dr.
Murakawa
has led
clinical
research
trials
for the
treatment
of
dermatologic
conditions
such as
tinea
capitis,
onychomycosis,
cutaneous
T-cell
lymphoma,
multiple
basal
cell
carcinoma,
seborrheic
dermatitis,
atopic
dermatitis,
and
psoriasis.
We are
actively
recruiting
patients
for many
studies
and
welcome
your
inquiries.
In
addition
to
clinical
trials,
our
group is
also
active
in
examining
health
care
policy.
Medical
students
have
been
instrumental
in
obtaining
valuable
data
concerning
this
issue.
We have
obtained
a better
understanding
about
who
provides
dermatological
care to
the
indigent
population
and how
this
care is
subsidized
in
Michigan
and
throughout
the
United
States.
Unfortunately,
fewer
academic
programs
and
government
funds
are
providing
this
safety
net for
the
un/underinsured,
forcing
private
entities
to
either
provide
charity
care or
close
their
doors to
this
population.
Our
clinics
have a
plethora
of
interesting
patient
cases.
Our
posters
and
presentations
have
been
displayed/presented
at
Michigan
Dermatological
Society
meetings,
American
Academy
of
Dermatology
meetings,
and
International
Investigative
Dermatology
meetings.
Members
of our
Clinical
Trials
Group:
 George
J.
Murakawa,
MD, PhD
- Dr.
Murakawa
completed
his PhD
in
microbiology
at UCLA,
received
his
medical
degree
from
Harvard,
completed
his
dermatology
residency
at UCSF,
served
as the
Residency
Director
of the
Division
of
Dermatology
at
Albany
Medical
College,
and was
Chairman
of the
Department
of
Dermatology
at Wayne
State
from
2000-4.
He is
the
principal
investigator
of our
studies.
He
continuously
looks
for
opportunities
to
broaden
our
group
and
expand
our
scope of
clinical
research.
Posters,
Presentations,
Manuscripts:
-
Trepte
JL,
Moossavi
M,
Murakawa
GJ.
"Providing
Dermatological
Care to
the
Indigent
Population
in
Detroit,
Michigan
and the
United
States."
Poster
#367
displayed
at the
61st
Annual
Meeting
of the
American
Academy
of
Dermatology
in San
Francisco,
CA,
March,
2003.
-
Murakawa
GJ,
Abdul-Khalek
R,
Trepte
JL.
"Providing
Dermatological
Care to
the
Indigent
Population."
Poster
# 0462
displayed
at the
International
Investigative
Dermatology
2003
Meeting
in
Miami
Beach,
FL,
April
30-May
4,
2003.
-
Abdul-Khalek
R,
Trepte
JL,
Murakawa
GJ.
"Utilization
of
Resources
in a
Practice
that
Provides
Care to
Private
Pay and
Indigent
Patients."
Poster
#0463
displayed
at the
International
Investigative
Dermatology
2003
Meeting
in
Miami
Beach,
FL,
April
30-May
4,
2003.
Other
Research
Links of
Interest:
The
development
of new
drugs
requires
intense
evaluation
by the
U.S.
Food and
Drug
Administration
(FDA).
This
review
process
consists
of
various
stages
of
testing.
Pre-clinical
testing
on
animals
precedes
testing
in
humans.
Often,
drugs
never
make it
past
this
stage.
Drug
sponsors
must
submit
an
Investigational
New Drug
Application
(IND) to
the FDA
prior to
testing
the drug
in human
subjects.
If the
FDA
approves
the IND,
then the
drug can
enter a
series
of
clinical
trials.
Phase I
studies
are
usually
small
and
serve to
determine
the
drug's
safety
and most
common
side
effects.
Phase II
studies
emphasize
how well
a drug
works
and
further
confirm
its
safety.
Phase
III
studies
investigate
the
ideal
dosing
of the
drug,
determine
how the
drug's
effectiveness
compares
to
standard
therapies,
and
continue
to
monitor
safety.
New Drug
Applications
include
information
from the
pre-clinical
testing
and
phase
I-III
data.
From
this
information,
the FDA
determines
whether
a drug
may be
marketed
in the
U.S.
Phase IV
studies
are
performed
after a
drug is
approved
for
marketing
by the
FDA.
These
range
from new
applications
of the
drug,
long-term
effects,
or
subject
responses
to
different
dosages
of the
drug.
|
